Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
90Y-huA33
- Development stage
- Unknown
- Lead developer
- Ludwig Cancer Research
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
90Y-huA33 is a radioimmunotherapeutic agent consisting of the humanized monoclonal antibody huA33 conjugated to the high-energy beta-emitting radioisotope Yttrium-90 (90Y) via the bifunctional chelator CHX-A″-DTPA. The antibody component, huA33, specifically targets Glycoprotein A33 (GPA33), a transmembrane protein that is highly and homogeneously expressed in over 95% of primary and metastatic colorectal cancers, while having restricted expression in normal intestinal mucosa. By binding to GPA33-positive tumor cells, 90Y-huA33 delivers localized ionizing radiation, which induces DNA damage and apoptosis in the targeted cells and neighboring cells through the crossfire effect. Developed by the Ludwig Institute for Cancer Research, 90Y-huA33 has been investigated in clinical trials for the treatment of colorectal cancer and is frequently used as an isotype control in preclinical studies for other IgG1-based radioimmunotherapies.
- Other names
- Yttrium-90 humanized A33Yttrium90 humanized A33Yttrium 90 humanized A3390Y-labeled huA33
02
Targets
GPA33 (Glycoprotein A33)
Beyond the preview
Go deeper on 90Y-huA33.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 90Y-huA33.